Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by saltajaon Nov 29, 2015 11:02am
308 Views
Post# 24336133

RE:RE:PIPERS JAFFRAYS CC

RE:RE:PIPERS JAFFRAYS CCI have been asking myself the same question.
If they show Blood Glucose level and Plasma Insulin level charts that look anything like the pre-clinical ones here: https://www.prometic.com/en/therapeutics/documents/ERA-EDTAposterPBI-4050TypeIIDiabetesLGFinal.pdf
then I think we are in for a good Tuesday.

I will also note the study outcomes listed here:
https://clinicaltrials.gov/ct2/show/NCT02562573?term=prometic&rank=3

I would expect read outs on all of these these.
  • Change from baseline on waist circumference [ Time Frame: 9 months ] [ Designated as safety issue: No ]
  • Change from baseline on biomarkers [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    % reduction and/or increase of biomarkers
  • Change from baseline on antidiabetic treatment [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    Treatment discontinued, dosing change, and/or new medication added
  • Change from baseline on triglycerides [ Time Frame: 9 months ] [ Designated as safety issue: No ]
  • Change from baseline on BP [ Time Frame: 9 months ] [ Designated as safety issue: No ]
  • Change from baseline on HDL-C [ Time Frame: 9 Months ] [ Designated as safety issue: No ]
  • Change from baseline on fasting plasma glucose [ Time Frame: 9 months ] [ Designated as safety issue: No ]

Bullboard Posts